Glaxosmithkline Pharmaceuticals Ltd Share Price
As on 13 June 2026 at 04:08 IST
GlaxoSmithKline Pharmaceuticals Q1 FY26 Results:
Profit for the period increased 12.4% to ₹205.01 crores in Q1 FY26, from ₹182.33 crores in Q1 FY25. Total income for the quarter decreased 0.2% year-on-year to ₹848.89 crores from ₹850.29 crores.
About Glaxosmithkline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) is a prominent research-based pharmaceutical and healthcare company. The company specializes in developing and marketing various prescription medicines and vaccines. It operates in the pharmaceutical sector. The company was founded on November 13, 1924, under H.J. Foster & Co. Limited. GlaxoSmithKline Pharmaceuticals Ltd headquarters is in Mumbai, Maharashtra, India. GSK India’s main products include a variety of prescription medicines and vaccines. The company’s medicines address many health conditions, while its vaccines help prevent diseases such as hepatitis A and B, pertussis, rotavirus, and cervical cancer. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-13.67%
Over 6 Months
-19.79%
Over 1 Year
-37.74%
Over 3 Years
51.59%
Glaxosmithkline Pharmaceuticals Ltd Summary
Close ₹2,103.20
Open ₹2,165
High ₹2,170
Low ₹2,096
Volume 2,38,350
Net Turnover (in Cr) ₹50.62
52Wk High ₹3,500
52Wk Low ₹2,096
52Wk High / Low
2,096
3,500
Glaxosmithkline Pharmaceuticals Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹35,629.48
EPS (TTM) 53.59
Book Value (BV) 132.30
Div. Yield 2.71 %
P/E (TTM) 35.20
Price/Book Value 15.89
Delivery % 70.66 %
Face Value 10
Key Ratios
PE Ratio 38.23
PB Ratio 17.26
EV to Sales 9.86
PEG Ratio 3.78
ROA 39.93
ROE 48.29
Debt-Equity 0.01
Net Profit Margin 26.70
Operating Profit Margin 38.14
Glaxosmithkline Pharmaceuticals Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Total Revenue | 3,967.03 | 3,895.14 | 3,576.30 | 3,352.38 | 3,353.80 |
| Total Expenses | 2,581.65 | 2,639.95 | 2,616.50 | 2,515.02 | 2,586.33 |
| Profit Before Tax | 1,406.01 | 1,259.88 | 816.19 | 836.40 | 779.05 |
| Profit After Tax | 1,035.98 | 927.58 | 589.96 | 607.64 | 380.77 |
| Operating Profit After Depreciation | 1,388.12 | 1,256.50 | 961.60 | 839.18 | 769.47 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Fixed Assets | 280.07 | 282.87 | 320.36 | 328.90 | 329.44 |
| Total Non Current Assets | 717.67 | 698.18 | 758.20 | 832.32 | 925.25 |
| Total Current Assets | 3,606.20 | 3,409.88 | 2,798.42 | 2,494.26 | 3,708.03 |
| Total Assets | 4,323.87 | 4,108.07 | 3,556.62 | 3,326.58 | 4,633.28 |
| Total Shareholder's Fund | 2,267.42 | 1,951.31 | 1,777.64 | 1,741.27 | 2,662.96 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 903.30 | 1,289.90 | 582.02 | 484.23 | 810.75 |
| Net Cash Used In Investing Activities | 396.98 | -45.80 | 8.71 | 807.85 | -405.51 |
| Net Cash Used In Financing Activities | -737.08 | -769.42 | -561.50 | -1,543.32 | -524.24 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Total Revenue | 3,932.76 | 3,866.05 | 3,530.73 | 3,317.86 | 3,293.72 |
| Total Expenses | 2,559.17 | 2,622.31 | 2,578.08 | 2,484.50 | 2,531.86 |
| Profit Before Tax | 1,376.23 | 1,248.44 | 809.04 | 832.39 | 773.44 |
| Profit After Tax | 1,011.82 | 919.05 | 584.69 | 604.71 | 376.58 |
| Operating Profit After Depreciation | 1,376.31 | 1,245.06 | 954.45 | 835.17 | 763.86 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Fixed Assets | 280.07 | 282.87 | 320.36 | 328.90 | 329.44 |
| Total Non Current Assets | 731.79 | 717.38 | 781.96 | 860.98 | 951.89 |
| Total Current Assets | 3,543.12 | 3,383.55 | 2,765.84 | 2,466.72 | 3,670.71 |
| Total Assets | 4,274.91 | 4,100.93 | 3,547.80 | 3,327.70 | 4,622.60 |
| Total Shareholder's Fund | 2,241.17 | 1,949.23 | 1,784.09 | 1,753 | 2,677.62 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 881.42 | 1,280.03 | 578.94 | 487.94 | 819.79 |
| Net Cash Used In Investing Activities | 385.25 | -36.53 | 14.97 | 805.19 | -419.66 |
| Net Cash Used In Financing Activities | -737.07 | -769.42 | -561.50 | -1,544.18 | -524.24 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 995.30 | 1,041.26 | 979.94 | 805.17 | 974.37 |
| Total Expenses | 644.37 | 669.92 | 644.21 | 553.97 | 641.18 |
| Profit Before Tax | 373.10 | 399.93 | 354 | 278.98 | 358.57 |
| Profit After Tax | 277.86 | 295.62 | 257.49 | 205.01 | 262.87 |
| Operating Profit after Depreciation | 386.88 | 403.46 | 369.30 | 294.92 | 373.87 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 989.15 | 1,022.59 | 973.63 | 804.83 | 966.08 |
| Total Expenses | 641.96 | 655.01 | 638.95 | 554.08 | 635.34 |
| Profit Before Tax | 369.12 | 377.89 | 350.65 | 278.57 | 354.90 |
| Profit After Tax | 274.94 | 277.18 | 255 | 204.70 | 260.14 |
| Operating Profit after Depreciation | 382.90 | 399.40 | 365.95 | 294.51 | 370.20 |
Glaxosmithkline Pharmaceuticals Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 2,076.13
S2 2,049.07
S3 2,002.13
Pivot 2,123.07
R1 2,150.13
R2 2,197.07
R3 2,224.13
Moving Average
20 SMA 2,262.97
50 SMA 2,343.15
100 SMA 2,405.16
200 SMA 2,519.99
Glaxosmithkline Pharmaceuticals Ltd Corporate Actions
Glaxosmithkline Pharmaceuticals Ltd
₹57.0/Share
Announcement Date 29 May 2026
Record Date 29 May 2026
Div Yield 570%
Glaxosmithkline Pharmaceuticals Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
Glaxosmithkline Pharmaceuticals Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Nippon India Pharma Fund | 2.34% |
| Aditya Birla SL MNC Fund | 1.49% |
| SBI Dividend Yield Fund | 1.20% |
| SBI Midcap Fund | 1.13% |
| Bajaj Finserv Flexi Cap Fund | 1.13% |
Glaxosmithkline Pharmaceuticals Ltd News
GSK Pharma gains as Q4 PAT rises 6% YoY to Rs 275 cr
Glaxosmithkline Pharmaceuticals rose 1.65% to Rs 2,446.60 after its standalone net profit jumped 5.68% to Rs 274.94 crore on 2.38% increase in revenue from operations to Rs 989.15 crore in Q4 FY26 over Q4 FY25.
14 May 2026, 09:23 am
GSK Pharma Q4 PAT rises 6% YoY to Rs 275 cr
Glaxosmithkline Pharmaceuticals' standalone net profit jumped 5.68% to Rs 274.94 crore on 2.38% increase in revenue from operations to Rs 989.15 crore in Q4 FY26 over Q4 FY25.
13 May 2026, 04:21 pm
GlaxoSmithKline Pharmaceuticals to hold AGM
On 30 June 2026
13 May 2026, 03:18 pm
Board of GlaxoSmithKline Pharmaceuticals recommends Final Dividend
Of Rs.57 per share
13 May 2026, 03:11 pm
GlaxoSmithKline Pharmaceuticals to announce Quarterly Result
On 13 May 2026
22 Apr 2026, 03:21 pm
Glaxosmithkline Pharmaceuticals Ltd Stock Analysis
- Annual revenue for Glaxosmithkline Pharmaceuticals Ltd increased by 1.73% to ₹3,932.76 crore in FY 2026 from ₹3,866.05 crore in FY 2025.
- Annual Net Profit for Glaxosmithkline Pharmaceuticals Ltd increased by 10.09% to ₹1,011.82 crore in FY 2026 from ₹919.05 crore in FY 2025.
- Promoter Shareholding in Glaxosmithkline Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 75% in December 2025 to 75% in March 2026.
- Glaxosmithkline Pharmaceuticals Ltd delivered a 1-year return of -37.74% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- Glaxosmithkline Pharmaceuticals Ltd share price moved down by 0.08% from its previous close of INR ₹2,103.20. The latest Glaxosmithkline Pharmaceuticals Ltd share price is INR ₹2,101.50.
- Glaxosmithkline Pharmaceuticals Ltd share price today has been at a low of 2,096 and a high of 2,131.90. Over the past 52 weeks, the Glaxosmithkline Pharmaceuticals Ltd share price has seen a low of 2,096 and a high of 3,500.
About Glaxosmithkline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) is a prominent research-based pharmaceutical and healthcare company. The company specializes in developing, manufacturing, and marketing various prescription medicines and vaccines. GSK India’s product portfolio covers various therapeutic areas. These include anti-infectives and respiratory diseases.
Operating in the pharmaceutical sector, GSK India has established itself as a significant player in the industry. The company was founded on November 13, 1924, under H.J. Foster & Co. Limited. With a century of experience, GSK India has grown substantially. It has expanded its product offerings and market reach both domestically and internationally.
GlaxoSmithKline Pharmaceuticals Ltd's headquarters is in Mumbai, Maharashtra, India. The company's promoters include Glaxo Group Limited, with a 35.99% stake. A team of professional managerial promoters manages the operations of the company that includes-
While GSK India is a significant player in the pharmaceutical sector, it is not the largest in terms of market share. It also does not hold the top position in market capitalization. However, it holds a strong position in specific therapeutic areas. This is particularly true in the development and distribution of vaccines. This leadership is a testament to the company’s expertise and commitment to quality and innovation. The registered office of GlaxoSmithKline Pharmaceuticals Ltd is in Mumbai, Maharashtra. The registrar's office is located in Hyderabad, Telangana.
The vision of GSK India emphasizes the importance of scientific innovation. The company invests heavily in research and development to create cutting-edge medicines and vaccines that tackle some of the world’s most challenging health issues. This focus on innovation ensures that GSK remains at the forefront of medical advancements, offering products that improve patient outcomes and enhance the quality of life. The company’s R&D efforts are directed toward developing new treatments for diseases such as cancer, respiratory conditions, and infectious diseases.
Quality is another cornerstone of GSK India’s vision. The company strives to maintain the highest standards in all its operations. This commitment extends from product development to manufacturing and distribution. GSK's commitment to quality is reflected in its rigorous quality control processes. It also adheres to international standards. This dedication to quality has earned the company a strong reputation. It is well-regarded by both healthcare professionals and patients. It has also helped the company build long-term relationships with its stakeholders.
Sustainability is a critical component of GSK India’s vision. The company recognizes the importance of environmental responsibility. It is committed to reducing its environmental footprint. GSK focuses on developing eco-friendly products and implementing sustainable manufacturing practices. The company aims to minimize waste and reduce energy consumption. It also focuses on using environmentally friendly materials.
GSK India’s vision also includes a strong focus on patient-centricity. The company aims to exceed patient expectations. It does this by providing high-quality products and exceptional service. GSK works closely with healthcare providers to understand the needs of patients. This collaboration helps them develop customized solutions that meet specific requirements. This patient-centric approach has helped the company build a loyal customer base and grow sustainably.
The company’s vision extends to its employees as well. GSK India believes its employees are its greatest asset and is committed to creating a positive and inclusive work environment. The company invests in employee development and provides continuous learning and growth opportunities. GSK’s vision includes fostering a culture of innovation, collaboration, and excellence, where employees feel valued and motivated to contribute to the company’s success.
GSK India’s vision also encompasses its role in the community. The company is committed to positively impacting society through its corporate social responsibility initiatives. GSK engages in various activities to improve community health, education, and well-being. The company’s vision includes supporting local communities and contributing to their development through sustainable and impactful initiatives.
The vision of GSK India is also reflected in its global expansion strategy. The company aims to strengthen its presence in existing markets and explore new opportunities in emerging markets. GSK’s global expansion is driven by a deep understanding of local markets and a commitment to delivering high-quality products that meet customers' specific needs in different regions. This global perspective is critical to the company’s vision and is essential for its long-term growth and success.
Operating in the pharmaceutical sector, GSK India has established itself as a significant player in the industry. The company was founded on November 13, 1924, under H.J. Foster & Co. Limited. With a century of experience, GSK India has grown substantially. It has expanded its product offerings and market reach both domestically and internationally.
GlaxoSmithKline Pharmaceuticals Ltd's headquarters is in Mumbai, Maharashtra, India. The company's promoters include Glaxo Group Limited, with a 35.99% stake. A team of professional managerial promoters manages the operations of the company that includes-
- R S Karnad
- B Akshikar
- J Chandy
- S Williams
- M Anand
While GSK India is a significant player in the pharmaceutical sector, it is not the largest in terms of market share. It also does not hold the top position in market capitalization. However, it holds a strong position in specific therapeutic areas. This is particularly true in the development and distribution of vaccines. This leadership is a testament to the company’s expertise and commitment to quality and innovation. The registered office of GlaxoSmithKline Pharmaceuticals Ltd is in Mumbai, Maharashtra. The registrar's office is located in Hyderabad, Telangana.
The vision of GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) has a clear and inspiring vision. This vision guides its operations and strategic initiatives. The company’s vision is to improve the quality of human life by enabling people to do more, feel better, and live longer. GSK India aims to be a leader in the pharmaceutical and healthcare sectors. It focuses on providing innovative and high-quality products. These products are designed to address the evolving needs of patients and healthcare providers.The vision of GSK India emphasizes the importance of scientific innovation. The company invests heavily in research and development to create cutting-edge medicines and vaccines that tackle some of the world’s most challenging health issues. This focus on innovation ensures that GSK remains at the forefront of medical advancements, offering products that improve patient outcomes and enhance the quality of life. The company’s R&D efforts are directed toward developing new treatments for diseases such as cancer, respiratory conditions, and infectious diseases.
Quality is another cornerstone of GSK India’s vision. The company strives to maintain the highest standards in all its operations. This commitment extends from product development to manufacturing and distribution. GSK's commitment to quality is reflected in its rigorous quality control processes. It also adheres to international standards. This dedication to quality has earned the company a strong reputation. It is well-regarded by both healthcare professionals and patients. It has also helped the company build long-term relationships with its stakeholders.
Sustainability is a critical component of GSK India’s vision. The company recognizes the importance of environmental responsibility. It is committed to reducing its environmental footprint. GSK focuses on developing eco-friendly products and implementing sustainable manufacturing practices. The company aims to minimize waste and reduce energy consumption. It also focuses on using environmentally friendly materials.
GSK India’s vision also includes a strong focus on patient-centricity. The company aims to exceed patient expectations. It does this by providing high-quality products and exceptional service. GSK works closely with healthcare providers to understand the needs of patients. This collaboration helps them develop customized solutions that meet specific requirements. This patient-centric approach has helped the company build a loyal customer base and grow sustainably.
The company’s vision extends to its employees as well. GSK India believes its employees are its greatest asset and is committed to creating a positive and inclusive work environment. The company invests in employee development and provides continuous learning and growth opportunities. GSK’s vision includes fostering a culture of innovation, collaboration, and excellence, where employees feel valued and motivated to contribute to the company’s success.
GSK India’s vision also encompasses its role in the community. The company is committed to positively impacting society through its corporate social responsibility initiatives. GSK engages in various activities to improve community health, education, and well-being. The company’s vision includes supporting local communities and contributing to their development through sustainable and impactful initiatives.
The vision of GSK India is also reflected in its global expansion strategy. The company aims to strengthen its presence in existing markets and explore new opportunities in emerging markets. GSK’s global expansion is driven by a deep understanding of local markets and a commitment to delivering high-quality products that meet customers' specific needs in different regions. This global perspective is critical to the company’s vision and is essential for its long-term growth and success.
FAQ’s
What is the share price of Glaxosmithkline Pharmaceuticals Ltd today?
Glaxosmithkline Pharmaceuticals Ltd share price as on 12 Jun 2026 is ₹ 2101.5
What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?
The market cap of Glaxosmithkline Pharmaceuticals Ltd stock is ₹35,629.48 Cr.
What is the PE Ratio of Glaxosmithkline Pharmaceuticals Ltd?
The Price to Earnings (P/E) Ratio of Glaxosmithkline Pharmaceuticals Ltd is 38.23
What is the PB Ratio of Glaxosmithkline Pharmaceuticals Ltd?
The Price to Book (P/B) Ratio of Glaxosmithkline Pharmaceuticals Ltd is 17.26
What is the 52 week high of Glaxosmithkline Pharmaceuticals Ltd Share Price?
The 52 week high of Glaxosmithkline Pharmaceuticals Ltd share price stands at ₹3,500
What is the 52 week low of Glaxosmithkline Pharmaceuticals Ltd Share Price?
The 52 week low of Glaxosmithkline Pharmaceuticals Ltd share price stands at ₹2,096
How can I buy shares of Glaxosmithkline Pharmaceuticals Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Glaxosmithkline Pharmaceuticals Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
